ES2233036T3 - Composicion farmaceutica que comprende factor viii y liposomas neutros. - Google Patents

Composicion farmaceutica que comprende factor viii y liposomas neutros.

Info

Publication number
ES2233036T3
ES2233036T3 ES99916022T ES99916022T ES2233036T3 ES 2233036 T3 ES2233036 T3 ES 2233036T3 ES 99916022 T ES99916022 T ES 99916022T ES 99916022 T ES99916022 T ES 99916022T ES 2233036 T3 ES2233036 T3 ES 2233036T3
Authority
ES
Spain
Prior art keywords
fviii
pharmaceutical composition
protein
colloidal particles
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99916022T
Other languages
English (en)
Spanish (es)
Inventor
Moshe Baru
Liliana Bar
Israel Nur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Opperbas Holding BV
Original Assignee
Opperbas Holding BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opperbas Holding BV filed Critical Opperbas Holding BV
Application granted granted Critical
Publication of ES2233036T3 publication Critical patent/ES2233036T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ES99916022T 1998-04-27 1999-04-23 Composicion farmaceutica que comprende factor viii y liposomas neutros. Expired - Lifetime ES2233036T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL12422498 1998-04-27
IL12422498 1998-04-27

Publications (1)

Publication Number Publication Date
ES2233036T3 true ES2233036T3 (es) 2005-06-01

Family

ID=11071435

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99916022T Expired - Lifetime ES2233036T3 (es) 1998-04-27 1999-04-23 Composicion farmaceutica que comprende factor viii y liposomas neutros.

Country Status (12)

Country Link
US (2) US6593294B1 (cg-RX-API-DMAC10.html)
EP (1) EP1079805B1 (cg-RX-API-DMAC10.html)
JP (1) JP4545928B2 (cg-RX-API-DMAC10.html)
AT (1) ATE283034T1 (cg-RX-API-DMAC10.html)
AU (1) AU747391B2 (cg-RX-API-DMAC10.html)
BR (1) BR9909978A (cg-RX-API-DMAC10.html)
CA (1) CA2329768C (cg-RX-API-DMAC10.html)
DE (1) DE69922189T2 (cg-RX-API-DMAC10.html)
ES (1) ES2233036T3 (cg-RX-API-DMAC10.html)
MX (1) MXPA00010241A (cg-RX-API-DMAC10.html)
PT (1) PT1079805E (cg-RX-API-DMAC10.html)
WO (1) WO1999055306A1 (cg-RX-API-DMAC10.html)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8110218B2 (en) 2000-11-30 2012-02-07 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein-lipid complexes
US20020132982A1 (en) * 2000-11-30 2002-09-19 Balasubramanian Sathyamangalam V. AHF associated dispersion system and method for preparation
US7625584B2 (en) * 2000-11-30 2009-12-01 The Research Foundation Of State University Of New York Method of complexing a protein by the use of a dispersed system and proteins thereof
DE60335469D1 (de) * 2002-07-02 2011-02-03 Univ Texas Radioaktiv markierte verbindungen und liposome und ihre herstellungs- und anwendungsverfahren
US7351688B2 (en) * 2003-02-05 2008-04-01 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein formulations
PT1633440E (pt) * 2003-04-15 2008-08-25 Opperbas Holding Bv Composição farmacêutica que compreende proteínas e/ou polipéptidos e partículas coloidais
WO2005017526A1 (en) * 2003-08-05 2005-02-24 The Research Foundation Of State University Of New York Reconstitution medium for protein and peptide formulations
US20070003607A1 (en) * 2003-09-02 2007-01-04 Vibhudutta Awasthi Neutral liposome-encapsulated compounds and methods of making and using thereof
US7208174B2 (en) * 2003-12-18 2007-04-24 Hoffmann-La Roche Inc. Liposome compositions
PL1713446T3 (pl) * 2004-01-23 2011-05-31 Camurus Ab Nielamelarne trójskładnikowe kompozycje lipidów
DK2371856T3 (en) 2004-11-12 2022-08-08 Bayer Healthcare Llc Site-directed modifikation af FVIII
US8895717B2 (en) * 2005-04-15 2014-11-25 The Board Of Regents Of The University Of Texas System Delivery of siRNA by neutral lipid compositions
BRPI0612843A2 (pt) * 2005-06-29 2010-11-30 The Research Foundation Of State University Of New York composição farmacêutica, métodos para fabricar a composição, e, uso de uma formulação
WO2007021822A2 (en) * 2005-08-09 2007-02-22 The Research Foundation Of State Of University Of New York At Buffalo Compositions and methods of preparation of liposomal microparticulate il-12
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
US7875288B2 (en) * 2006-03-30 2011-01-25 The Research Foundation Of State University Of New York Method for treating blood coagulation disorders
EP2007357B1 (en) * 2006-03-30 2016-11-09 The Research Foundation Of State University Of New York Compositions of less immunogenic and long-circulating protein-lipid complexes
DK2101821T3 (da) * 2006-12-15 2014-10-06 Baxter Healthcare Sa Faktor VIIA-(poly)sialinsyre-konjugat med forlænget halveringstid in vivo
WO2008077616A1 (en) 2006-12-22 2008-07-03 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
EP2865760B1 (en) 2008-06-24 2017-10-11 CSL Behring GmbH Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
EP2299953B1 (en) 2008-07-14 2017-04-12 Polypid Ltd. Sustained-release drug carrier composition
WO2010135714A2 (en) 2009-05-22 2010-11-25 The Methodist Hospital Research Institute Methods for modulating adipocyte expression using microrna compositions
CN102470105B (zh) 2009-07-14 2015-07-29 波利皮得有限公司 持续释放药物载体组合物
US10058837B2 (en) 2009-08-28 2018-08-28 The Trustees Of Columbia University In The City Of New York Systems, methods, and devices for production of gas-filled microbubbles
US20130028959A1 (en) 2009-12-16 2013-01-31 Massachusetts Institute Of Technology Liposomes for Preventing the Spread of HIV
EP2512588A4 (en) 2009-12-16 2014-06-04 Univ Columbia METHODS, DEVICES AND SYSTEMS FOR ULTRASOUND-RELEASED ON-DEMAND AGGREGATE FREEZING
JP5860409B2 (ja) 2010-01-19 2016-02-16 ポリピッド リミテッド 徐放性核酸マトリックス組成物
US8637448B2 (en) 2010-09-14 2014-01-28 University Of Rochester Recombinant factor VIII having enhanced stability following mutation at the A1-C2 domain interface
DE102010043733A1 (de) 2010-11-10 2012-05-10 Oxprotect Gmbh Unbeladene PEGylierte Liposomen zur Verwendung als Arzneimittel zur Prophylaxe und Therapie von hämorrhagischen und thrombo- embolischen Erkrankungen
US9458223B2 (en) 2012-02-15 2016-10-04 Csl Behring Gmbh Von willebrand factor variants having improved factor VIII binding affinity
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
DK3164150T3 (da) 2014-07-02 2021-02-08 CSL Behring Lengnau AG Modificeret von willebrand-faktor
GB201417589D0 (en) 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
SG11201706659WA (en) 2015-03-06 2017-09-28 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
CA2986625A1 (en) 2015-05-22 2016-12-01 Csl Behring Recombinant Facility Ag Methods for preparing modified von willebrand factor
CA2986626A1 (en) 2015-05-22 2016-12-01 Csl Behring Recombinant Facility Ag Truncated von willebrand factor polypeptides for treating hemophilia
GB201518170D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
GB201518171D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
GB201518172D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
SG11201805494WA (en) 2016-01-07 2018-07-30 Csl Behring Recombinant Facility Ag Mutated von willebrand factor
AU2017204955B2 (en) 2016-01-07 2021-04-01 CSL Behring Lengnau AG Mutated truncated von Willebrand Factor
WO2017220099A1 (en) 2016-06-24 2017-12-28 Statens Serum Institut Adjuvants with modified drainage properties
WO2018005657A1 (en) 2016-06-28 2018-01-04 Verily Life Sciences Llc Serial filtration to generate small cholesterol-containing liposomes
DK3538133T3 (da) 2016-11-11 2021-04-19 CSL Behring Lengnau AG Trunkeret von willebrand faktor polypeptider til behandling af hæmofili
JP2020504082A (ja) 2016-11-11 2020-02-06 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 血液凝固障害の処置又は予防における血管外投与のための切断型フォン・ヴィルブランド因子ポリペプチド
GB202111757D0 (en) * 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles for use in the treatment of haemophilia A

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7900459A (nl) 1979-01-19 1980-07-22 Hendrik Coenraad Hemker Prof D Farmaceutisch preparaat en werkwijze ter bereiding daarvan.
JPS56127307A (en) * 1980-03-11 1981-10-06 Green Cross Corp:The Blood-coagulation factor 8 pharmaceutical for oral administration
US4348384A (en) 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5527528A (en) * 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
WO1991012021A2 (en) * 1990-02-13 1991-08-22 Oxford Virology Plc Therapeutic agents, and intermediates for the synthesis thereof
US6326353B1 (en) * 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method

Also Published As

Publication number Publication date
MXPA00010241A (es) 2004-09-06
EP1079805A1 (en) 2001-03-07
AU3441499A (en) 1999-11-16
CA2329768A1 (en) 1999-11-04
CA2329768C (en) 2008-06-10
ATE283034T1 (de) 2004-12-15
DE69922189D1 (de) 2004-12-30
US6930087B2 (en) 2005-08-16
BR9909978A (pt) 2000-12-26
AU747391B2 (en) 2002-05-16
JP2002512947A (ja) 2002-05-08
WO1999055306A1 (en) 1999-11-04
PT1079805E (pt) 2005-03-31
JP4545928B2 (ja) 2010-09-15
US6593294B1 (en) 2003-07-15
DE69922189T2 (de) 2005-11-10
EP1079805B1 (en) 2004-11-24
US20030134778A1 (en) 2003-07-17

Similar Documents

Publication Publication Date Title
US6593294B1 (en) Pharmaceutical composition comprising Factor VIII and neutral liposomes
US20240366732A1 (en) Modified colloidal particles for use in the treatment of haemophilia a
Baru et al. Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy
Scott et al. Therapy of von Willebrand disease
ES2259674T3 (es) Liposomas de encapsulacion de farmacos anticancerosos y utilizacion de los mismos en el tratamiento de tumores malignos.
ES2407134T3 (es) Composiciones hemostáticas farmacéuticamente estables
ES2307009T3 (es) Composicion farmaceutica que contiene proteinas y/o polipeptidos y particulas coloidales.
US11484499B2 (en) Pharmaceutical formulations of PEGylated liposomes and blood coagulation factors
US20030232075A1 (en) Compositions for producing factor Xa
Fatouros et al. Recombinant factor VIII SQ—stability of VIII: C in homogenates from porcine, monkey and human subcutaneous tissue
IL139053A (en) Pharmaceutical composition comprising factor VIII and neutral colloidal particles
US20240358801A1 (en) Modified colloidal particles for use in the treatment of haemophilia a
US20250064738A1 (en) Modified colloidal particles for use in the treatment of haemophilia a
Castaman et al. Haematological care of the haemophilic patient
Lisman et al. Mechanism of action of recombinant activated Factor VII